Immune checkpoint protein predicts poor prostate cancer outcomes

Key clinical point: The immune checkpoint protein B7-H3 expression correlated positively with androgen receptor expression and was associated with biochemical and clinical recurrence in prostate cancer.

Major finding: Researchers identified B7-H3 positivity in 15% of prostate cancer patients in a Spanish cohort and 38% of patients in a Norwegian cohort. B7-H3 expression was significantly associated with biochemical recurrence in the Spanish cohort (P = .003) and with clinical recurrence in the Norwegian cohort (P = .005).

Study details: The data come from an immunohistochemistry analysis of tissue samples from a total of 327 prostate adenocarcinoma patients who underwent radical prostatectomy; 120 from Spain and 206 from Norway.

,

Disclosures: The study was funded by the Instituto de Salud Carlos III, the Ministerio de Economía y Competitividad, the Research Council of Norway, Marie Skłodowska-Curie Actions, Radiumhospitalets legater, Norway, and UNIFOR-FRIMED legater, Norway. The researchers had no financial conflicts to disclose.

Source: Nunes-Xavier CE et al. Prostate. 2021 Jun 14. doi: 10.1002/pros.24180.